{
    "id": 30,
    "premise": "none",
    "hypothesis": "Inhibiting \u03b2-catenin may be effective in treating patients with activating CTTNB1 mutations.",
    "label": "entailment",
    "explanation": "Activating mutations of CTNNB1 promote proliferation of cells via \u03b2-catenin.",
    "results": {
        "semantic validity": false,
        "premise": null,
        "hypothesis": "Inhibiting \u03b2-catenin may be effective in treating patients with activating CTTNB1 mutations.",
        "history explanation": [
            "0 iteration: Activating mutations of CTNNB1 promote proliferation of cells via \u03b2-catenin.",
            "1 iteration: Activating mutations of CTNNB1 promote proliferation of cells via \u03b2-catenin.\nInhibiting \u03b2-catenin can reduce or stop the proliferation of cells caused by activating mutations of CTNNB",
            "2 iteration: Activating mutations of CTNNB1 promote proliferation of cells via \u03b2-catenin.\nInhibiting \u03b2-catenin can reduce or stop the proliferation of cells caused by activating mutations of CTNNB.\nReducing or stopping the proliferation of cells through inhibiting \u03b2-catenin can be considered a treatment for patients with activating CTNNB1 mutations.",
            "3 iteration: Activating mutations of CTNNB1 promote proliferation of cells via \u03b2-catenin.\nInhibiting \u03b2-catenin can reduce or stop the proliferation of cells caused by activating mutations of CTNNBReducing or stopping the proliferation of cells through inhibiting \u03b2-catenin is considered an effective treatment for patients with activating CTNNB1 mutations.",
            "4 iteration: Activating mutations of CTNNB1 promote proliferation of cells via \u03b2-catenin.\nInhibiting \u03b2-catenin can reduce or stop the proliferation of cells caused by activating mutations of CTNNBReducing or stopping the proliferation of cells through inhibiting \u03b2-catenin is considered an effective treatment for patients with activating CTNNB1 mutations.",
            "5 iteration: Activating mutations of CTNNB1 promote the proliferation of cells via \u03b2-catenin.\nInhibiting \u03b2-catenin can reduce or stop the proliferation of cells caused by activating mutations of CTNNB1, and this reduction or cessation is a crucial step in treating these mutations.\nReducing or stopping the proliferation of cells through inhibiting \u03b2-catenin is considered an effective treatment for patients with activating CTNNB1 mutations, as it directly addresses the underlying cause of cell proliferation.",
            "6 iteration: Activating mutations of CTNNB1 promote the proliferation of cells via \u03b2-catenin.\nInhibiting \u03b2-catenin can reduce or stop the proliferation of cells caused by activating mutations of CTNNB1, and this reduction or cessation is a crucial step in treating these mutations.\nReducing or stopping the proliferation of cells through inhibiting \u03b2-catenin directly addresses the underlying cause of cell proliferation, making it an effective treatment for patients with activating CTNNB1 mutations.\nThe effectiveness of inhibiting \u03b2-catenin as a treatment is due to its ability to target the specific pathway that leads to cell proliferation in patients with activating CTNNB1 mutations.",
            "7 iteration: Activating mutations of CTNNB1 promote the proliferation of cells via \u03b2-catenin.\nInhibiting \u03b2-catenin can reduce or stop the proliferation of cells caused by activating mutations of CTNNB1, and this reduction or cessation is a crucial step in treating these mutations.\nReducing or stopping the proliferation of cells through inhibiting \u03b2-catenin directly addresses the underlying cause of cell proliferation, making it an effective treatment for patients with activating CTNNB1 mutations.\nThe effectiveness of inhibiting \u03b2-catenin as a treatment is due to its ability to target the specific pathway that leads to cell proliferation in patients with activating CTNNB1 mutations.\nInhibiting \u03b2-catenin not only reduces cell proliferation but also enhances the effectiveness of treatment for patients with activating CTNNB1 mutations by directly targeting the pathway responsible for cell proliferation.",
            "8 iteration: Activating mutations of CTNNB1 promote the proliferation of cells via \u03b2-catenin.\nInhibiting \u03b2-catenin can reduce or stop the proliferation of cells caused by activating mutations of CTNNB1, and this reduction or cessation is a crucial step in treating these mutations.\nReducing or stopping the proliferation of cells through inhibiting \u03b2-catenin directly addresses the underlying cause of cell proliferation, making it an effective treatment for patients with activating CTNNB1 mutations.\nThe effectiveness of inhibiting \u03b2-catenin as a treatment is due to its ability to target the specific pathway that leads to cell proliferation in patients with activating CTNNB1 mutations, thereby directly contributing to the treatment's success.\nInhibiting \u03b2-catenin not only reduces cell proliferation but also enhances the effectiveness of treatment for patients with activating CTNNB1 mutations by directly targeting the pathway responsible for cell proliferation, ensuring the treatment is effective.",
            "9 iteration: Activating mutations of CTNNB1 promote the proliferation of cells via \u03b2-catenin.\nInhibiting \u03b2-catenin can reduce or stop the proliferation of cells caused by activating mutations of CTNNB1, and this reduction or cessation is a crucial step in treating these mutations.\nReducing or stopping the proliferation of cells through inhibiting \u03b2-catenin directly addresses the underlying cause of cell proliferation, making it an effective treatment for patients with activating CTNNB1 mutations.\nThe effectiveness of inhibiting \u03b2-catenin as a treatment is due to its ability to target the specific pathway that leads to cell proliferation in patients with activating CTNNB1 mutations, thereby directly contributing to the treatment's success.\nInhibiting \u03b2-catenin not only reduces cell proliferation but also enhances the effectiveness of treatment for patients with activating CTNNB1 mutations by directly targeting the pathway responsible for cell proliferation, ensuring the treatment is effective.",
            "10 iteration: Activating mutations of CTNNB1 promote the proliferation of cells via \u03b2-catenin.\nInhibiting \u03b2-catenin can reduce or stop the proliferation of cells caused by activating mutations of CTNNB1, and this reduction or cessation is a crucial step in treating these mutations.\nReducing or stopping the proliferation of cells through inhibiting \u03b2-catenin directly addresses the underlying cause of cell proliferation, making it an effective treatment for patients with activating CTNNB1 mutations.\nThe effectiveness of inhibiting \u03b2-catenin as a treatment is due to its ability to target the specific pathway that leads to cell proliferation in patients with activating CTNNB1 mutations, thereby directly contributing to the treatment's success.\nInhibiting \u03b2-catenin not only reduces cell proliferation but also enhances the effectiveness of treatment for patients with activating CTNNB1 mutations by directly targeting the pathway responsible for cell proliferation, ensuring the treatment is effective."
        ],
        "history semantic validity": [
            "0 iteration: False",
            "1 iteration: False",
            "2 iteration: False",
            "3 iteration: False",
            "4 iteration: False",
            "5 iteration: False",
            "6 iteration: False",
            "7 iteration: False",
            "8 iteration: False",
            "9 iteration: False",
            "10 iteration: False"
        ],
        "history critique output": [
            "0 iteration: {'syntactic validity': True, 'error code': '(* To prove the hypothesis, we need to show that inhibiting \u03b2-catenin may be effective in treating patients with activating CTNNB1 mutations. *)\\n(* We assume inhibiting \u03b2-catenin as an event e1 and treating as an event e2. *)\\n(* We need to show that these events are effective and involve the known entities. *)\\nthen have \"\u2203e1 e2. Inhibit e1 \u2227 \u03b2Catenin x \u2227 Patient e1 x \u2227 Effective e2 \u2227 Treat e2 \u2227 Patient e2 y \u2227 Mutation y \u2227 Activating y \u2227 CTNNB1 y\" sledgehammer', 'solving time': 118.86730098724365, 'proof tactics': [], 'code': 'theory clinical_30_0\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Mutation :: \"entity \u21d2 bool\"\\n  Activating :: \"entity \u21d2 bool\"\\n  CTNNB1 :: \"entity \u21d2 bool\"\\n  Proliferation :: \"entity \u21d2 bool\"\\n  Cell :: \"entity \u21d2 bool\"\\n  Promote :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  \u03b2Catenin :: \"entity \u21d2 bool\"\\n  Via :: \"event \u21d2 entity \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n  Effective :: \"event \u21d2 bool\"\\n  Treat :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Activating mutations of CTNNB1 promote proliferation of cells via \u03b2-catenin. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. Mutation x \u2227 Activating x \u2227 CTNNB1 x \u2227 Proliferation y \u2227 Cell y \u2227 Promote e \u2227 Agent e x \u2227 Patient e y \u2227 \u03b2Catenin z \u2227 Via e z\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"\u03b2Catenin x \u2227 Mutation y \u2227 Activating y \u2227 CTNNB1 y\"\\n  (* Hypothesis: Inhibiting \u03b2-catenin may be effective in treating patients with activating CTTNB1 mutations. *)\\n  shows \"\u2203x y e1 e2. Inhibit e1 \u2227 \u03b2Catenin x \u2227 Patient e1 x \u2227 Effective e2 \u2227 Treat e2 \u2227 Patient e2 y \u2227 Mutation y \u2227 Activating y \u2227 CTNNB1 y\"\\nproof -\\n  (* From the premise, we have known information about \u03b2-catenin and activating mutations of CTNNB1. *)\\n  from asm have \"\u03b2Catenin x \u2227 Mutation y \u2227 Activating y \u2227 CTNNB1 y\" <ATP>\\n  (* Explanation 1 provides a logical relation: Implies(A, C), Implies(activating mutations of CTNNB1, via \u03b2-catenin) *)\\n  (* Since we have activating mutations of CTNNB1, we can infer via \u03b2-catenin. *)\\n  then have \"\u03b2Catenin x\" <ATP>\\n  (* To prove the hypothesis, we need to show that inhibiting \u03b2-catenin may be effective in treating patients with activating CTNNB1 mutations. *)\\n  (* We assume inhibiting \u03b2-catenin as an event e1 and treating as an event e2. *)\\n  (* We need to show that these events are effective and involve the known entities. *)\\n  then have \"\u2203e1 e2. Inhibit e1 \u2227 \u03b2Catenin x \u2227 Patient e1 x \u2227 Effective e2 \u2227 Treat e2 \u2227 Patient e2 y \u2227 Mutation y \u2227 Activating y \u2227 CTNNB1 y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: activating mutations of CTNNB1 (from Explanatory Sentence 1)\\nB: proliferation of cells (from Explanatory Sentence 1)\\nC: via \u03b2-catenin (from Explanatory Sentence 1)\\n\\nLogical Relations:\\nImplies(A, And(B, C))\\nImplies(activating mutations of CTNNB1, B & C)\\n--------\\n\\nDerived Implications:\\nImplies(A, C)\\nImplies(activating mutations of CTNNB1, via \u03b2-catenin)\\n--------\\nImplies(A, B)\\nImplies(activating mutations of CTNNB1, proliferation of cells)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(via \u03b2-catenin), Not(activating mutations of CTNNB1))\\n--------\\nImplies(Not(B), Not(A))\\nImplies(Not(proliferation of cells), Not(activating mutations of CTNNB1))\\n--------\\n'}",
            "1 iteration: {'syntactic validity': True, 'error code': '(* We can infer that if inhibiting \u03b2-catenin reduces or stops proliferation, it may be considered a treatment. *)\\nhave \"Inhibit e1 \u2227 \u03b2Catenin x \u2227 PatientEntity y \u2227 Mutation y \u2227 CTNNB1 y \u2227 Activating y \u2227 Treat e2 \u2227 Agent e2 x \u2227 Patient e2 y\" sledgehammer', 'solving time': 103.17840361595154, 'proof tactics': [], 'code': 'theory clinical_30_1\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Mutation :: \"entity \u21d2 bool\"\\n  CTNNB1 :: \"entity \u21d2 bool\"\\n  Activating :: \"entity \u21d2 bool\"\\n  Proliferation :: \"entity \u21d2 bool\"\\n  Cell :: \"entity \u21d2 bool\"\\n  \u03b2Catenin :: \"entity \u21d2 bool\"\\n  Promote :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Via :: \"entity \u21d2 entity \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n  CTNNB :: \"entity \u21d2 bool\"\\n  Reduce :: \"event \u21d2 bool\"\\n  Stop :: \"event \u21d2 bool\"\\n  Cause :: \"entity \u21d2 entity \u21d2 bool\"\\n  Treat :: \"event \u21d2 bool\"\\n  PatientEntity :: \"entity \u21d2 bool\"  (* Renamed to avoid conflict with Patient as event *)\\n\\n(* Explanation 1: Activating mutations of CTNNB1 promote proliferation of cells via \u03b2-catenin. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. Mutation x \u2227 CTNNB1 x \u2227 Activating x \u2227 Proliferation y \u2227 Cell y \u2227 \u03b2Catenin z \u2227 Promote e \u2227 Agent e x \u2227 Patient e y \u2227 Via y z\"\\n\\n(* Explanation 2: Inhibiting \u03b2-catenin can reduce or stop the proliferation of cells caused by activating mutations of CTNNB. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2. Inhibit e1 \u2227 \u03b2Catenin x \u2227 Proliferation y \u2227 Cell y \u2227 Mutation z \u2227 CTNNB z \u2227 Activating z \u2227 (Reduce e2 \u2228 Stop e2) \u2227 Agent e2 x \u2227 Patient e2 y \u2227 Cause y z\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"\u03b2Catenin x \u2227 PatientEntity y \u2227 Mutation y \u2227 CTNNB1 y \u2227 Activating y\"\\n  (* Hypothesis: Inhibiting \u03b2-catenin may be effective in treating patients with activating CTNNB1 mutations. *)\\n  shows \"\u2203x y e1 e2. Inhibit e1 \u2227 \u03b2Catenin x \u2227 PatientEntity y \u2227 Mutation y \u2227 CTNNB1 y \u2227 Activating y \u2227 Treat e2 \u2227 Agent e2 x \u2227 Patient e2 y\"\\nproof -\\n  (* From the known information, we have \u03b2Catenin x, PatientEntity y, Mutation y, CTNNB1 y, and Activating y. *)\\n  from asm have \"\u03b2Catenin x \u2227 PatientEntity y \u2227 Mutation y \u2227 CTNNB1 y \u2227 Activating y\" <ATP>\\n  \\n  (* Explanation 1 states that activating mutations of CTNNB1 promote proliferation of cells via \u03b2-catenin. *)\\n  (* Explanation 2 states that inhibiting \u03b2-catenin can reduce or stop the proliferation of cells caused by activating mutations of CTNNB. *)\\n  (* We have a logical relation Implies(D, Not(B)), which means inhibiting \u03b2-catenin implies not proliferation of cells. *)\\n  (* This suggests that inhibiting \u03b2-catenin can counteract the effects of activating mutations of CTNNB1. *)\\n  \\n  (* To show that inhibiting \u03b2-catenin may be effective in treating patients with activating CTNNB1 mutations, *)\\n  (* we need to establish a connection between inhibiting \u03b2-catenin and treating the patient. *)\\n  (* Explanation 2 provides a basis for this by indicating that inhibiting \u03b2-catenin can reduce or stop proliferation. *)\\n  \\n  (* We can infer that if inhibiting \u03b2-catenin reduces or stops proliferation, it may be considered a treatment. *)\\n  have \"Inhibit e1 \u2227 \u03b2Catenin x \u2227 PatientEntity y \u2227 Mutation y \u2227 CTNNB1 y \u2227 Activating y \u2227 Treat e2 \u2227 Agent e2 x \u2227 Patient e2 y\" <ATP>\\n  \\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: activating mutations of CTNNB1 (from Explanatory Sentence 1)\\nB: proliferation of cells (from Explanatory Sentence 1)\\nC: \u03b2-catenin (from Explanatory Sentence 1 and 2)\\nD: inhibiting \u03b2-catenin (from Explanatory Sentence 2)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(activating mutations of CTNNB1, proliferation of cells)\\n--------\\nImplies(D, Not(B))\\nImplies(inhibiting \u03b2-catenin, Not(proliferation of cells))\\n--------\\n\\nDerived Implications:\\nImplies(A, Not(D))\\nImplies(activating mutations of CTNNB1, Not(inhibiting \u03b2-catenin))\\n--------\\nImplies(D, Not(A))\\nImplies(inhibiting \u03b2-catenin, Not(activating mutations of CTNNB1))\\n--------\\n'}",
            "2 iteration: {'syntactic validity': True, 'error code': '(* Explanation 2 provides that inhibiting \u03b2-catenin can reduce or stop the proliferation of cells caused by activating mutations of CTNNB. *)\\n(* This implies that inhibiting \u03b2-catenin can prevent the proliferation of cells. *)\\n(* Explanation 3 states that reducing or stopping the proliferation of cells through inhibiting \u03b2-catenin can be considered a treatment for patients with activating CTNNB1 mutations. *)\\n(* Therefore, inhibiting \u03b2-catenin is effective in treating patients with activating CTNNB1 mutations. *)\\nthen have \"\u2203e1 e2. Inhibit e1 \u2227 \u03b2Catenin x \u2227 Patient e1 x \u2227 Effective e2 \u2227 Treat e2 \u2227 Patient e2 y \u2227 Mutation y \u2227 Activating y \u2227 CTTNB1 y\" sledgehammer', 'solving time': 103.1861252784729, 'proof tactics': [], 'code': 'theory clinical_30_2\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Mutation :: \"entity \u21d2 bool\"\\n  Activating :: \"entity \u21d2 bool\"\\n  CTNNB1 :: \"entity \u21d2 bool\"\\n  Proliferation :: \"entity \u21d2 bool\"\\n  Cell :: \"entity \u21d2 bool\"\\n  Promote :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  \u03b2Catenin :: \"entity \u21d2 bool\"\\n  Via :: \"event \u21d2 entity \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n  Reduce :: \"event \u21d2 bool\"\\n  Stop :: \"event \u21d2 bool\"\\n  Cause :: \"event \u21d2 entity \u21d2 bool\"\\n  Through :: \"event \u21d2 event \u21d2 bool\"\\n  Consider :: \"event \u21d2 bool\"\\n  Treatment :: \"event \u21d2 bool\"\\n  Effective :: \"event \u21d2 bool\"\\n  Treat :: \"event \u21d2 bool\"\\n  CTTNB1 :: \"entity \u21d2 bool\"\\n  CTNNB :: \"entity \u21d2 bool\"  (* Added missing constant definition *)\\n\\n(* Explanation 1: Activating mutations of CTNNB1 promote proliferation of cells via \u03b2-catenin. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. Mutation x \u2227 Activating x \u2227 CTNNB1 x \u2227 Proliferation y \u2227 Cell y \u2227 Promote e \u2227 Agent e x \u2227 Patient e y \u2227 \u03b2Catenin z \u2227 Via e z\"\\n\\n(* Explanation 2: Inhibiting \u03b2-catenin can reduce or stop the proliferation of cells caused by activating mutations of CTNNB. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2. Inhibit e1 \u2227 \u03b2Catenin x \u2227 Proliferation y \u2227 Cell y \u2227 (Reduce e2 \u2228 Stop e2) \u2227 Agent e2 x \u2227 Patient e2 y \u2227 Cause e2 z \u2227 Mutation z \u2227 Activating z \u2227 CTNNB z\"\\n\\n(* Explanation 3: Reducing or stopping the proliferation of cells through inhibiting \u03b2-catenin can be considered a treatment for patients with activating CTNNB1 mutations. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z w e1 e2 e3. (Reduce e1 \u2228 Stop e1) \u2227 Proliferation x \u2227 Cell x \u2227 Inhibit e2 \u2227 \u03b2Catenin y \u2227 Through e1 e2 \u2227 Consider e3 \u2227 Treatment e3 \u2227 Patient e3 z \u2227 Mutation z \u2227 Activating z \u2227 CTNNB1 z\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"\u03b2Catenin x \u2227 Mutation y \u2227 Activating y \u2227 CTTNB1 y\"\\n  (* Hypothesis: Inhibiting \u03b2-catenin may be effective in treating patients with activating CTTNB1 mutations. *)\\n  shows \"\u2203x y e1 e2. Inhibit e1 \u2227 \u03b2Catenin x \u2227 Patient e1 x \u2227 Effective e2 \u2227 Treat e2 \u2227 Patient e2 y \u2227 Mutation y \u2227 Activating y \u2227 CTTNB1 y\"\\nproof -\\n  (* From the known information, we have \u03b2Catenin x, Mutation y, Activating y, and CTTNB1 y. *)\\n  from asm have \"\u03b2Catenin x \u2227 Mutation y \u2227 Activating y \u2227 CTTNB1 y\" <ATP>\\n  (* Explanation 2 provides that inhibiting \u03b2-catenin can reduce or stop the proliferation of cells caused by activating mutations of CTNNB. *)\\n  (* This implies that inhibiting \u03b2-catenin can prevent the proliferation of cells. *)\\n  (* Explanation 3 states that reducing or stopping the proliferation of cells through inhibiting \u03b2-catenin can be considered a treatment for patients with activating CTNNB1 mutations. *)\\n  (* Therefore, inhibiting \u03b2-catenin is effective in treating patients with activating CTNNB1 mutations. *)\\n  then have \"\u2203e1 e2. Inhibit e1 \u2227 \u03b2Catenin x \u2227 Patient e1 x \u2227 Effective e2 \u2227 Treat e2 \u2227 Patient e2 y \u2227 Mutation y \u2227 Activating y \u2227 CTTNB1 y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: activating mutations of CTNNB1 (from Explanatory Sentence 1)\\nB: proliferation of cells (from Explanatory Sentence 1)\\nC: \u03b2-catenin (from Explanatory Sentence 1)\\nD: inhibiting \u03b2-catenin (from Explanatory Sentence 2)\\nE: treatment for patients with activating CTNNB1 mutations (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, Implies(C, B))\\nImplies(activating mutations of CTNNB1, Implies(\u03b2-catenin, proliferation of cells))\\n--------\\nImplies(D, Not(B))\\nImplies(inhibiting \u03b2-catenin, Not(proliferation of cells))\\n--------\\nImplies(D, E)\\nImplies(inhibiting \u03b2-catenin, treatment for patients with activating CTNNB1 mutations)\\n--------\\n\\nDerived Implications:\\n'}",
            "3 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 10.38567304611206, 'proof tactics': ['Type unification failed: Clash of types \"event\" and \"entity\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  Agent e2 :: entity \\\\<Rightarrow> bool\\nOperand:   e1 :: event\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_30_3\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Mutation :: \"entity \u21d2 bool\"\\n  CTNNB1 :: \"entity \u21d2 bool\"\\n  Activating :: \"entity \u21d2 bool\"\\n  Cell :: \"entity \u21d2 bool\"\\n  Proliferation :: \"entity \u21d2 bool\"\\n  Promote :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Via :: \"event \u21d2 entity \u21d2 bool\"\\n  \u03b2Catenin :: \"entity \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n  Reduce :: \"event \u21d2 bool\"\\n  Stop :: \"event \u21d2 bool\"\\n  Cause :: \"event \u21d2 entity \u21d2 bool\"\\n  Through :: \"event \u21d2 event \u21d2 bool\"\\n  Considered :: \"event \u21d2 bool\"\\n  Effective :: \"event \u21d2 bool\"\\n  Treatment :: \"event \u21d2 bool\"\\n  For :: \"event \u21d2 entity \u21d2 bool\"\\n  Treat :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Activating mutations of CTNNB1 promote proliferation of cells via \u03b2-catenin. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. Mutation x \u2227 CTNNB1 x \u2227 Activating x \u2227 Cell y \u2227 Proliferation z \u2227 Promote e \u2227 Agent e x \u2227 Patient e z \u2227 Via e z \u2227 \u03b2Catenin z\"\\n\\n(* Explanation 2: Inhibiting \u03b2-catenin can reduce or stop the proliferation of cells caused by activating mutations of CTNNB1. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2. Inhibit e1 \u2227 \u03b2Catenin x \u2227 Proliferation y \u2227 Cell z \u2227 Mutation z \u2227 CTNNB1 z \u2227 Activating z \u2227 Agent e1 x \u2227 (Reduce e2 \u2228 Stop e2) \u2227 Agent e2 x \u2227 Patient e2 y \u2227 Cause e2 z\"\\n\\n(* Explanation 3: Reducing or stopping the proliferation of cells through inhibiting \u03b2-catenin is considered an effective treatment for patients with activating CTNNB1 mutations. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2 e3. Proliferation x \u2227 Cell y \u2227 Inhibit e1 \u2227 \u03b2Catenin z \u2227 Mutation y \u2227 CTNNB1 y \u2227 Activating y \u2227 (Reduce e2 \u2228 Stop e2) \u2227 Agent e2 z \u2227 Patient e2 x \u2227 Through e2 e1 \u2227 Considered e3 \u2227 Agent e3 z \u2227 Effective e3 \u2227 Treatment e3 \u2227 For e3 y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"\u03b2Catenin x \u2227 Mutation y \u2227 CTNNB1 y \u2227 Activating y\"\\n  (* Hypothesis: Inhibiting \u03b2-catenin may be effective in treating patients with activating CTTNB1 mutations. *)\\n  shows \"\u2203x y e1 e2. Inhibit e1 \u2227 \u03b2Catenin x \u2227 Mutation y \u2227 CTNNB1 y \u2227 Activating y \u2227 Agent e1 x \u2227 Treat e2 \u2227 Agent e2 e1 \u2227 Patient e2 y \u2227 Effective e2\"\\nproof -\\n  (* From the premise, we have known information about \u03b2-catenin, mutation, CTNNB1, and activating. *)\\n  from asm have \"\u03b2Catenin x \u2227 Mutation y \u2227 CTNNB1 y \u2227 Activating y\" <ATP>\\n  (* Explanation 2 provides a logical relation Implies(D, Not(B)), Implies(inhibiting \u03b2-catenin, Not(proliferation of cells)) *)\\n  (* Explanation 3 provides a logical relation Implies(D, E), Implies(inhibiting \u03b2-catenin, effective treatment for patients with activating CTNNB1 mutations) *)\\n  (* We can use these relations to infer the hypothesis. *)\\n  then have \"\u2203e1 e2. Inhibit e1 \u2227 Agent e1 x \u2227 Treat e2 \u2227 Agent e2 e1 \u2227 Patient e2 y \u2227 Effective e2\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: activating mutations of CTNNB1 (from Explanatory Sentence 1)\\nB: proliferation of cells (from Explanatory Sentence 1)\\nC: \u03b2-catenin (from Explanatory Sentence 1)\\nD: inhibiting \u03b2-catenin (from Explanatory Sentence 2)\\nE: effective treatment for patients with activating CTNNB1 mutations (from Explanatory Sentence 2)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(activating mutations of CTNNB1, proliferation of cells)\\n--------\\nImplies(D, Not(B))\\nImplies(inhibiting \u03b2-catenin, Not(proliferation of cells))\\n--------\\nImplies(D, E)\\nImplies(inhibiting \u03b2-catenin, effective treatment for patients with activating CTNNB1 mutations)\\n--------\\n\\nDerived Implications:\\nImplies(A, Not(D))\\nImplies(activating mutations of CTNNB1, Not(inhibiting \u03b2-catenin))\\n--------\\nImplies(D, Not(A))\\nImplies(inhibiting \u03b2-catenin, Not(activating mutations of CTNNB1))\\n--------\\n'}",
            "4 iteration: {'syntactic validity': True, 'error code': '(* Explanation 2 provides a logical relation: Implies(D, E), Implies(inhibiting \u03b2-catenin, effective treatment for patients with activating CTNNB1 mutations) *)\\n(* We need to show that inhibiting \u03b2-catenin is effective in treating patients with activating CTNNB1 mutations. *)\\n(* Explanation 3 supports this by stating that reducing or stopping the proliferation of cells through inhibiting \u03b2-catenin is considered an effective treatment. *)\\nfrom explanation_3 have \"\u2203e1 e2. Inhibit e1 \u2227 \u03b2Catenin x \u2227 Mutation y \u2227 Activating y \u2227 CTNNB1 y \u2227 Agent e1 x \u2227 Effective e2 \u2227 Treatment e2 \u2227 For e2 y\" sledgehammer', 'solving time': 103.70803904533386, 'proof tactics': [], 'code': 'theory clinical_30_4\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Mutation :: \"entity \u21d2 bool\"\\n  Activating :: \"entity \u21d2 bool\"\\n  CTNNB1 :: \"entity \u21d2 bool\"\\n  Proliferation :: \"entity \u21d2 bool\"\\n  Cell :: \"entity \u21d2 bool\"\\n  Promote :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Via :: \"event \u21d2 entity \u21d2 bool\"\\n  \u03b2Catenin :: \"entity \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n  Reduce :: \"event \u21d2 bool\"\\n  Stop :: \"event \u21d2 bool\"\\n  Cause :: \"event \u21d2 entity \u21d2 bool\"\\n  Considered :: \"event \u21d2 bool\"\\n  Effective :: \"event \u21d2 bool\"\\n  Treatment :: \"event \u21d2 bool\"\\n  For :: \"event \u21d2 entity \u21d2 bool\"\\n  Through :: \"event \u21d2 event \u21d2 bool\"\\n  Treat :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Activating mutations of CTNNB1 promote proliferation of cells via \u03b2-catenin. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. Mutation x \u2227 Activating x \u2227 CTNNB1 x \u2227 Proliferation y \u2227 Cell z \u2227 Promote e \u2227 Agent e x \u2227 Patient e y \u2227 Via e z \u2227 \u03b2Catenin z\"\\n\\n(* Explanation 2: Inhibiting \u03b2-catenin can reduce or stop the proliferation of cells caused by activating mutations of CTNNB1. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2. Inhibit e1 \u2227 \u03b2Catenin x \u2227 Proliferation y \u2227 Cell z \u2227 Mutation z \u2227 Activating z \u2227 CTNNB1 z \u2227 (Reduce e2 \u2228 Stop e2) \u2227 Agent e1 x \u2227 Patient e2 y \u2227 Cause e2 z\"\\n\\n(* Explanation 3: Reducing or stopping the proliferation of cells through inhibiting \u03b2-catenin is considered an effective treatment for patients with activating CTNNB1 mutations. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2 e3. Proliferation x \u2227 Cell y \u2227 Inhibit e1 \u2227 \u03b2Catenin z \u2227 Mutation z \u2227 Activating z \u2227 CTNNB1 z \u2227 (Reduce e2 \u2228 Stop e2) \u2227 Agent e1 z \u2227 Patient e2 x \u2227 Through e2 e1 \u2227 Considered e3 \u2227 Effective e3 \u2227 Treatment e3 \u2227 For e3 z\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"\u03b2Catenin x \u2227 Mutation y \u2227 Activating y \u2227 CTNNB1 y\"\\n  (* Hypothesis: Inhibiting \u03b2-catenin may be effective in treating patients with activating CTTNB1 mutations. *)\\n  shows \"\u2203x y e1 e2. Inhibit e1 \u2227 \u03b2Catenin x \u2227 Mutation y \u2227 Activating y \u2227 CTNNB1 y \u2227 Agent e1 x \u2227 Effective e2 \u2227 Treat e2 \u2227 Agent e2 x \u2227 Patient e2 y\"\\nproof -\\n  (* From the premise, we have known information about \u03b2-catenin and activating mutations of CTNNB1. *)\\n  from asm have \"\u03b2Catenin x \u2227 Mutation y \u2227 Activating y \u2227 CTNNB1 y\" <ATP>\\n  (* Explanation 2 provides a logical relation: Implies(D, E), Implies(inhibiting \u03b2-catenin, effective treatment for patients with activating CTNNB1 mutations) *)\\n  (* We need to show that inhibiting \u03b2-catenin is effective in treating patients with activating CTNNB1 mutations. *)\\n  (* Explanation 3 supports this by stating that reducing or stopping the proliferation of cells through inhibiting \u03b2-catenin is considered an effective treatment. *)\\n  from explanation_3 have \"\u2203e1 e2. Inhibit e1 \u2227 \u03b2Catenin x \u2227 Mutation y \u2227 Activating y \u2227 CTNNB1 y \u2227 Agent e1 x \u2227 Effective e2 \u2227 Treatment e2 \u2227 For e2 y\" <ATP>\\n  (* Therefore, we can conclude that inhibiting \u03b2-catenin may be effective in treating patients with activating CTNNB1 mutations. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: activating mutations of CTNNB1 (from Explanatory Sentence 1)\\nB: proliferation of cells (from Explanatory Sentence 1)\\nC: \u03b2-catenin (from Explanatory Sentence 1)\\nD: inhibiting \u03b2-catenin (from Explanatory Sentence 2)\\nE: effective treatment for patients with activating CTNNB1 mutations (from Explanatory Sentence 2)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(activating mutations of CTNNB1, proliferation of cells)\\n--------\\nImplies(A, C)\\nImplies(activating mutations of CTNNB1, \u03b2-catenin)\\n--------\\nImplies(D, Not(B))\\nImplies(inhibiting \u03b2-catenin, Not(proliferation of cells))\\n--------\\nImplies(D, E)\\nImplies(inhibiting \u03b2-catenin, effective treatment for patients with activating CTNNB1 mutations)\\n--------\\n\\nDerived Implications:\\nImplies(A, Not(D))\\nImplies(activating mutations of CTNNB1, Not(inhibiting \u03b2-catenin))\\n--------\\nImplies(D, Not(A))\\nImplies(inhibiting \u03b2-catenin, Not(activating mutations of CTNNB1))\\n--------\\n'}",
            "5 iteration: {'syntactic validity': True, 'error code': '(* We have a logical relation Implies(D, F), which states that inhibiting \u03b2-catenin leads to effective treatment for patients with activating CTNNB1 mutations. *)\\n(* Explanation 2 provides that inhibiting \u03b2-catenin can reduce or stop the proliferation of cells caused by activating mutations of CTNNB1. *)\\n(* Explanation 3 states that reducing or stopping the proliferation of cells through inhibiting \u03b2-catenin is considered an effective treatment. *)\\n(* Therefore, we can infer that inhibiting \u03b2-catenin may be effective in treating patients with activating CTNNB1 mutations. *)\\nthen have \"\u2203e1 e2. Inhibit e1 \u2227 \u03b2Catenin x \u2227 Agent e1 x \u2227 Effective e2 \u2227 Treat e2 \u2227 Patient e2 y \u2227 Mutations y \u2227 Activating y \u2227 CTNNB1 y\" sledgehammer', 'solving time': 103.17796874046326, 'proof tactics': [], 'code': 'theory clinical_30_5\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Mutations :: \"entity \u21d2 bool\"\\n  Activating :: \"entity \u21d2 bool\"\\n  CTNNB1 :: \"entity \u21d2 bool\"\\n  Proliferation :: \"entity \u21d2 bool\"\\n  Cells :: \"entity \u21d2 bool\"\\n  Promote :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Via :: \"event \u21d2 entity \u21d2 bool\"\\n  \u03b2Catenin :: \"entity \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n  Reduce :: \"event \u21d2 bool\"\\n  Stop :: \"event \u21d2 bool\"\\n  Cause :: \"event \u21d2 entity \u21d2 bool\"\\n  ReductionOrCessation :: \"entity \u21d2 bool\"\\n  CrucialStep :: \"entity \u21d2 bool\"\\n  Treat :: \"event \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Purpose :: \"event \u21d2 event \u21d2 bool\"\\n  EffectiveTreatment :: \"event \u21d2 bool\"\\n  Through :: \"event \u21d2 event \u21d2 bool\"\\n  Address :: \"event \u21d2 bool\"\\n  Directly :: \"event \u21d2 bool\"\\n  Effective :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Activating mutations of CTNNB1 promote the proliferation of cells via \u03b2-catenin. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. Mutations x \u2227 Activating x \u2227 CTNNB1 x \u2227 Proliferation y \u2227 Cells y \u2227 Promote e \u2227 Agent e x \u2227 Patient e y \u2227 Via e z \u2227 \u03b2Catenin z\"\\n\\n(* Explanation 2: Inhibiting \u03b2-catenin can reduce or stop the proliferation of cells caused by activating mutations of CTNNB1, and this reduction or cessation is a crucial step in treating these mutations. *)\\naxiomatization where\\n  explanation_2_1: \"\u2203x y z e1 e2. Inhibit e1 \u2227 \u03b2Catenin x \u2227 Agent e1 x \u2227 Proliferation y \u2227 Cells y \u2227 (Reduce e2 \u2228 Stop e2) \u2227 Agent e2 x \u2227 Patient e2 y \u2227 Cause e2 z \u2227 Mutations z \u2227 Activating z \u2227 CTNNB1 z\"\\n\\naxiomatization where\\n  explanation_2_2: \"\u2203x y e1 e2. ReductionOrCessation x \u2227 CrucialStep y \u2227 Treat e1 \u2227 Mutations y \u2227 In x y \u2227 Purpose e1 e2\"\\n\\n(* Explanation 3: Reducing or stopping the proliferation of cells through inhibiting \u03b2-catenin is considered an effective treatment for patients with activating CTNNB1 mutations, as it directly addresses the underlying cause of cell proliferation. *)\\naxiomatization where\\n  explanation_3_1: \"\u2203x y z e1 e2 e3. (Reduce e1 \u2228 Stop e1) \u2227 Proliferation x \u2227 Cells x \u2227 Inhibit e2 \u2227 \u03b2Catenin y \u2227 Agent e2 y \u2227 Through e1 e2 \u2227 EffectiveTreatment e3 \u2227 Patient e3 z \u2227 Mutations z \u2227 Activating z \u2227 CTNNB1 z\"\\n\\naxiomatization where\\n  explanation_3_2: \"\u2203x y e. Cause e x \u2227 Proliferation y \u2227 Cells y \u2227 Address e \u2227 Directly e \u2227 Agent e x \u2227 Patient e y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"\u03b2Catenin x \u2227 Mutations y \u2227 Activating y \u2227 CTNNB1 y\"\\n  (* Hypothesis: Inhibiting \u03b2-catenin may be effective in treating patients with activating CTNNB1 mutations *)\\n  shows \"\u2203x y e1 e2. Inhibit e1 \u2227 \u03b2Catenin x \u2227 Agent e1 x \u2227 Effective e2 \u2227 Treat e2 \u2227 Patient e2 y \u2227 Mutations y \u2227 Activating y \u2227 CTNNB1 y\"\\nproof -\\n  (* From the premise, we have known information about \u03b2-catenin and activating mutations of CTNNB1. *)\\n  from asm have \"\u03b2Catenin x \u2227 Mutations y \u2227 Activating y \u2227 CTNNB1 y\" <ATP>\\n  (* We have a logical relation Implies(D, F), which states that inhibiting \u03b2-catenin leads to effective treatment for patients with activating CTNNB1 mutations. *)\\n  (* Explanation 2 provides that inhibiting \u03b2-catenin can reduce or stop the proliferation of cells caused by activating mutations of CTNNB1. *)\\n  (* Explanation 3 states that reducing or stopping the proliferation of cells through inhibiting \u03b2-catenin is considered an effective treatment. *)\\n  (* Therefore, we can infer that inhibiting \u03b2-catenin may be effective in treating patients with activating CTNNB1 mutations. *)\\n  then have \"\u2203e1 e2. Inhibit e1 \u2227 \u03b2Catenin x \u2227 Agent e1 x \u2227 Effective e2 \u2227 Treat e2 \u2227 Patient e2 y \u2227 Mutations y \u2227 Activating y \u2227 CTNNB1 y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: activating mutations of CTNNB1 (from Explanatory Sentence 1)\\nB: proliferation of cells (from Explanatory Sentence 1)\\nC: \u03b2-catenin (from Explanatory Sentence 1)\\nD: inhibiting \u03b2-catenin (from Explanatory Sentence 2)\\nE: reduction or cessation of cell proliferation (from Explanatory Sentence 2)\\nF: effective treatment for patients with activating CTNNB1 mutations (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, Implies(C, B))\\nImplies(activating mutations of CTNNB1, Implies(\u03b2-catenin, proliferation of cells))\\n--------\\nImplies(D, E)\\nImplies(inhibiting \u03b2-catenin, reduction or cessation of cell proliferation)\\n--------\\nImplies(E, F)\\nImplies(reduction or cessation of cell proliferation, effective treatment for patients with activating CTNNB1 mutations)\\n--------\\n\\nDerived Implications:\\nImplies(D, F)\\nImplies(inhibiting \u03b2-catenin, effective treatment for patients with activating CTNNB1 mutations)\\n--------\\nImplies(Not(F), Not(D))\\nImplies(Not(effective treatment for patients with activating CTNNB1 mutations), Not(inhibiting \u03b2-catenin))\\n--------\\n'}",
            "6 iteration: {'syntactic validity': True, 'error code': '(* We need to show that inhibiting \u03b2-catenin may be effective in treating patients with activating CTNNB1 mutations. *)\\n(* From the logical relations, we have Implies(D, H), which means inhibiting \u03b2-catenin implies the effectiveness of treatment. *)\\n(* We also have Implies(D, F), which means inhibiting \u03b2-catenin implies treatment for activating CTNNB1 mutations. *)\\n(* Therefore, if we assume inhibiting \u03b2-catenin, we can infer both the effectiveness of treatment and treatment for activating CTNNB1 mutations. *)\\nhave \"Inhibit e1 \u2227 \u03b2Catenin x \u2227 Agent e1 x\" sledgehammer', 'solving time': 103.01955437660217, 'proof tactics': [], 'code': 'theory clinical_30_6\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Mutation :: \"entity \u21d2 bool\"\\n  Activating :: \"entity \u21d2 bool\"\\n  CTNNB1 :: \"entity \u21d2 bool\"\\n  Proliferation :: \"entity \u21d2 bool\"\\n  Cell :: \"entity \u21d2 bool\"\\n  \u03b2Catenin :: \"entity \u21d2 bool\"\\n  Promote :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Via :: \"event \u21d2 entity \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n  Reduce :: \"event \u21d2 bool\"\\n  Stop :: \"event \u21d2 bool\"\\n  Cause :: \"entity \u21d2 entity \u21d2 bool\"\\n  CrucialStep :: \"event \u21d2 event \u21d2 bool\"\\n  Treat :: \"event \u21d2 bool\"\\n  Address :: \"event \u21d2 bool\"\\n  Through :: \"event \u21d2 event \u21d2 bool\"\\n  Directly :: \"event \u21d2 bool\"\\n  Make :: \"event \u21d2 bool\"\\n  EffectiveTreatment :: \"event \u21d2 bool\"\\n  PatientEntity :: \"entity \u21d2 bool\"\\n  Effectiveness :: \"event \u21d2 bool\"\\n  Treatment :: \"event \u21d2 bool\"\\n  Ability :: \"event \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Pathway :: \"entity \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Effective :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Activating mutations of CTNNB1 promote the proliferation of cells via \u03b2-catenin. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. Mutation x \u2227 Activating x \u2227 CTNNB1 x \u2227 Proliferation y \u2227 Cell y \u2227 \u03b2Catenin z \u2227 Promote e \u2227 Agent e x \u2227 Patient e y \u2227 Via e z\"\\n\\n(* Explanation 2: Inhibiting \u03b2-catenin can reduce or stop the proliferation of cells caused by activating mutations of CTNNB1, and this reduction or cessation is a crucial step in treating these mutations. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2 e3. Inhibit e1 \u2227 \u03b2Catenin x \u2227 Proliferation y \u2227 Cell y \u2227 Mutation z \u2227 Activating z \u2227 CTNNB1 z \u2227 Reduce e2 \u2227 Stop e3 \u2227 Agent e2 x \u2227 Agent e3 x \u2227 Patient e2 y \u2227 Patient e3 y \u2227 Cause z y \u2227 CrucialStep e2 e3 \u2227 Treat e2 \u2227 Treat e3 \u2227 Patient e2 z \u2227 Patient e3 z\"\\n\\n(* Explanation 3: Reducing or stopping the proliferation of cells through inhibiting \u03b2-catenin directly addresses the underlying cause of cell proliferation, making it an effective treatment for patients with activating CTNNB1 mutations. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z w e1 e2 e3 e4. Reduce e1 \u2227 Stop e2 \u2227 Proliferation y \u2227 Cell y \u2227 Inhibit e3 \u2227 \u03b2Catenin x \u2227 Cause z y \u2227 Address e4 \u2227 Agent e1 x \u2227 Agent e2 x \u2227 Agent e3 x \u2227 Patient e1 y \u2227 Patient e2 y \u2227 Through e1 e3 \u2227 Through e2 e3 \u2227 Directly e4 \u2227 Patient e4 z \u2227 Make e4 \u2227 EffectiveTreatment e4 \u2227 PatientEntity w \u2227 Mutation w \u2227 Activating w \u2227 CTNNB1 w\"\\n\\n(* Explanation 4: The effectiveness of inhibiting \u03b2-catenin as a treatment is due to its ability to target the specific pathway that leads to cell proliferation in patients with activating CTNNB1 mutations. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z w e1 e2 e3. Effectiveness e1 \u2227 Inhibit e2 \u2227 \u03b2Catenin x \u2227 Treatment e1 \u2227 Ability e3 \u2227 Target e3 \u2227 Pathway y \u2227 Lead e3 \u2227 Proliferation z \u2227 Cell z \u2227 PatientEntity w \u2227 Mutation w \u2227 Activating w \u2227 CTNNB1 w \u2227 Agent e2 x \u2227 Patient e3 y \u2227 Patient e3 z \u2227 In z w\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"\u03b2Catenin x \u2227 PatientEntity y \u2227 Mutation y \u2227 Activating y \u2227 CTNNB1 y\"\\n  (* Hypothesis: Inhibiting \u03b2-catenin may be effective in treating patients with activating CTTNB1 mutations. *)\\n  shows \"\u2203x y e1 e2. Inhibit e1 \u2227 \u03b2Catenin x \u2227 PatientEntity y \u2227 Mutation y \u2227 Activating y \u2227 CTNNB1 y \u2227 Agent e1 x \u2227 Effective e2 \u2227 Treat e2 \u2227 Patient e2 y\"\\nproof -\\n  (* From the premise, we have known information about \u03b2-catenin, patient entity, mutation, activating, and CTNNB1. *)\\n  from asm have \"\u03b2Catenin x \u2227 PatientEntity y \u2227 Mutation y \u2227 Activating y \u2227 CTNNB1 y\" <ATP>\\n  (* We need to show that inhibiting \u03b2-catenin may be effective in treating patients with activating CTNNB1 mutations. *)\\n  (* From the logical relations, we have Implies(D, H), which means inhibiting \u03b2-catenin implies the effectiveness of treatment. *)\\n  (* We also have Implies(D, F), which means inhibiting \u03b2-catenin implies treatment for activating CTNNB1 mutations. *)\\n  (* Therefore, if we assume inhibiting \u03b2-catenin, we can infer both the effectiveness of treatment and treatment for activating CTNNB1 mutations. *)\\n  have \"Inhibit e1 \u2227 \u03b2Catenin x \u2227 Agent e1 x\" <ATP>\\n  then have \"Effective e2 \u2227 Treat e2 \u2227 Patient e2 y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: activating mutations of CTNNB1 (from Explanatory Sentence 1)\\nB: proliferation of cells (from Explanatory Sentence 1)\\nC: \u03b2-catenin (from Explanatory Sentence 1)\\nD: inhibiting \u03b2-catenin (from Explanatory Sentence 2)\\nE: reduction or cessation of cell proliferation (from Explanatory Sentence 2)\\nF: treatment for activating CTNNB1 mutations (from Explanatory Sentence 2)\\nG: addressing the underlying cause of cell proliferation (from Explanatory Sentence 3)\\nH: effectiveness of treatment (from Explanatory Sentence 4)\\nI: targeting the specific pathway (from Explanatory Sentence 4)\\n\\nLogical Relations:\\nImplies(A, Implies(C, B))\\nImplies(activating mutations of CTNNB1, Implies(\u03b2-catenin, proliferation of cells))\\n--------\\nImplies(D, E)\\nImplies(inhibiting \u03b2-catenin, reduction or cessation of cell proliferation)\\n--------\\nImplies(E, F)\\nImplies(reduction or cessation of cell proliferation, treatment for activating CTNNB1 mutations)\\n--------\\nImplies(E, G)\\nImplies(reduction or cessation of cell proliferation, addressing the underlying cause of cell proliferation)\\n--------\\nImplies(D, I)\\nImplies(inhibiting \u03b2-catenin, targeting the specific pathway)\\n--------\\nImplies(I, H)\\nImplies(targeting the specific pathway, effectiveness of treatment)\\n--------\\n\\nDerived Implications:\\nImplies(D, G)\\nImplies(inhibiting \u03b2-catenin, addressing the underlying cause of cell proliferation)\\n--------\\nImplies(Not(G), Not(D))\\nImplies(Not(addressing the underlying cause of cell proliferation), Not(inhibiting \u03b2-catenin))\\n--------\\nImplies(Not(F), Not(D))\\nImplies(Not(treatment for activating CTNNB1 mutations), Not(inhibiting \u03b2-catenin))\\n--------\\nImplies(Not(H), Not(D))\\nImplies(Not(effectiveness of treatment), Not(inhibiting \u03b2-catenin))\\n--------\\nImplies(D, F)\\nImplies(inhibiting \u03b2-catenin, treatment for activating CTNNB1 mutations)\\n--------\\nImplies(D, H)\\nImplies(inhibiting \u03b2-catenin, effectiveness of treatment)\\n--------\\n'}",
            "7 iteration: {'syntactic validity': True, 'error code': '(* There is a logical relation Implies(D, F), Implies(inhibiting \u03b2-catenin, treatment for activating CTNNB1 mutations) *)\\n(* We need to show that inhibiting \u03b2-catenin is effective in treating patients with activating CTNNB1 mutations. *)\\n(* From explanation 2, we know that inhibiting \u03b2-catenin can reduce or stop the proliferation of cells caused by activating mutations of CTNNB1, and this reduction or cessation is a crucial step in treating these mutations. *)\\n(* From explanation 5, inhibiting \u03b2-catenin not only reduces cell proliferation but also enhances the effectiveness of treatment for patients with activating CTNNB1 mutations. *)\\n(* Therefore, inhibiting \u03b2-catenin is effective in treating patients with activating CTNNB1 mutations. *)\\nthen have \"\u2203e1 e2. Inhibit e1 \u2227 \u03b2Catenin x \u2227 Agent e1 x \u2227 Effective e2 \u2227 Treat e2 \u2227 Patient e2 y\" sledgehammer', 'solving time': 102.97779703140259, 'proof tactics': [], 'code': 'theory clinical_30_7\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Mutation :: \"entity \u21d2 bool\"\\n  Activating :: \"entity \u21d2 bool\"\\n  CTNNB1 :: \"entity \u21d2 bool\"\\n  Proliferation :: \"entity \u21d2 bool\"\\n  Cell :: \"entity \u21d2 bool\"\\n  \u03b2Catenin :: \"entity \u21d2 bool\"\\n  Promote :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Via :: \"event \u21d2 entity \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n  Reduce :: \"event \u21d2 bool\"\\n  Stop :: \"event \u21d2 bool\"\\n  Cause :: \"event \u21d2 entity \u21d2 bool\"\\n  CrucialStep :: \"event \u21d2 bool\"\\n  Treat :: \"event \u21d2 bool\"\\n  Address :: \"event \u21d2 bool\"\\n  Directly :: \"event \u21d2 bool\"\\n  Make :: \"event \u21d2 bool\"\\n  EffectiveTreatment :: \"event \u21d2 bool\"\\n  Effective :: \"event \u21d2 bool\"\\n  Treatment :: \"event \u21d2 bool\"\\n  Ability :: \"event \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Pathway :: \"entity \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  PatientEntity :: \"entity \u21d2 bool\"  (* Renamed to avoid conflict *)\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Enhance :: \"event \u21d2 bool\"\\n  ResponsibleFor :: \"event \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Activating mutations of CTNNB1 promote the proliferation of cells via \u03b2-catenin *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. Mutation x \u2227 Activating x \u2227 CTNNB1 x \u2227 Proliferation y \u2227 Cell z \u2227 \u03b2Catenin z \u2227 Promote e \u2227 Agent e x \u2227 Patient e y \u2227 Via e z\"\\n\\n(* Explanation 2: Inhibiting \u03b2-catenin can reduce or stop the proliferation of cells caused by activating mutations of CTNNB1, and this reduction or cessation is a crucial step in treating these mutations *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2 e3. Inhibit e1 \u2227 \u03b2Catenin x \u2227 Proliferation y \u2227 Cell z \u2227 Mutation z \u2227 Activating z \u2227 CTNNB1 z \u2227 Reduce e2 \u2227 Stop e3 \u2227 Agent e2 x \u2227 Agent e3 x \u2227 Patient e2 y \u2227 Patient e3 y \u2227 Cause e2 z \u2227 Cause e3 z \u2227 CrucialStep e2 \u2227 CrucialStep e3 \u2227 Treat e2 \u2227 Treat e3 \u2227 Patient e2 z \u2227 Patient e3 z\"\\n\\n(* Explanation 3: Reducing or stopping the proliferation of cells through inhibiting \u03b2-catenin directly addresses the underlying cause of cell proliferation, making it an effective treatment for patients with activating CTNNB1 mutations *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z w e1 e2 e3 e4. Reduce e1 \u2227 Stop e2 \u2227 Proliferation y \u2227 Cell z \u2227 Inhibit e3 \u2227 \u03b2Catenin x \u2227 Cause e4 w \u2227 Address e4 \u2227 Agent e1 x \u2227 Agent e2 x \u2227 Agent e3 x \u2227 Agent e4 x \u2227 Patient e1 y \u2227 Patient e2 y \u2227 Patient e4 w \u2227 Directly e4 \u2227 Make e4 \u2227 EffectiveTreatment e4 \u2227 Patient e4 z \u2227 Mutation z \u2227 Activating z \u2227 CTNNB1 z\"\\n\\n(* Explanation 4: The effectiveness of inhibiting \u03b2-catenin as a treatment is due to its ability to target the specific pathway that leads to cell proliferation in patients with activating CTNNB1 mutations *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z w e1 e2 e3. Effective e1 \u2227 Inhibit e2 \u2227 \u03b2Catenin x \u2227 Treatment e1 \u2227 Ability e3 \u2227 Target e3 \u2227 Pathway y \u2227 Lead e3 \u2227 Proliferation z \u2227 Cell z \u2227 PatientEntity w \u2227 Mutation w \u2227 Activating w \u2227 CTNNB1 w \u2227 Agent e2 x \u2227 Agent e3 x \u2227 Patient e3 y \u2227 Patient e3 z \u2227 In w z\"\\n\\n(* Explanation 5: Inhibiting \u03b2-catenin not only reduces cell proliferation but also enhances the effectiveness of treatment for patients with activating CTNNB1 mutations by directly targeting the pathway responsible for cell proliferation *)\\naxiomatization where\\n  explanation_5: \"\u2203x y z w e1 e2 e3 e4. Inhibit e1 \u2227 \u03b2Catenin x \u2227 Proliferation y \u2227 Cell y \u2227 Reduce e2 \u2227 Enhance e3 \u2227 EffectiveTreatment e3 \u2227 PatientEntity z \u2227 Mutation z \u2227 Activating z \u2227 CTNNB1 z \u2227 Pathway w \u2227 Target e4 \u2227 ResponsibleFor e4 y \u2227 Directly e4 \u2227 Agent e1 x \u2227 Agent e2 x \u2227 Agent e3 x \u2227 Agent e4 x \u2227 Patient e2 y \u2227 Patient e3 z \u2227 Patient e4 w\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"\u03b2Catenin x \u2227 PatientEntity y \u2227 Mutation y \u2227 Activating y \u2227 CTNNB1 y\"\\n  (* Hypothesis: Inhibiting \u03b2-catenin may be effective in treating patients with activating CTTNB1 mutations *)\\n  shows \"\u2203x y e1 e2. Inhibit e1 \u2227 \u03b2Catenin x \u2227 PatientEntity y \u2227 Mutation y \u2227 Activating y \u2227 CTNNB1 y \u2227 Agent e1 x \u2227 Effective e2 \u2227 Treat e2 \u2227 Patient e2 y\"\\nproof -\\n  (* From the premise, we have known information about \u03b2-catenin, patient entity, mutation, activating, and CTNNB1. *)\\n  from asm have \"\u03b2Catenin x \u2227 PatientEntity y \u2227 Mutation y \u2227 Activating y \u2227 CTNNB1 y\" <ATP>\\n  (* There is a logical relation Implies(D, F), Implies(inhibiting \u03b2-catenin, treatment for activating CTNNB1 mutations) *)\\n  (* We need to show that inhibiting \u03b2-catenin is effective in treating patients with activating CTNNB1 mutations. *)\\n  (* From explanation 2, we know that inhibiting \u03b2-catenin can reduce or stop the proliferation of cells caused by activating mutations of CTNNB1, and this reduction or cessation is a crucial step in treating these mutations. *)\\n  (* From explanation 5, inhibiting \u03b2-catenin not only reduces cell proliferation but also enhances the effectiveness of treatment for patients with activating CTNNB1 mutations. *)\\n  (* Therefore, inhibiting \u03b2-catenin is effective in treating patients with activating CTNNB1 mutations. *)\\n  then have \"\u2203e1 e2. Inhibit e1 \u2227 \u03b2Catenin x \u2227 Agent e1 x \u2227 Effective e2 \u2227 Treat e2 \u2227 Patient e2 y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: activating mutations of CTNNB1 (from Explanatory Sentence 1)\\nB: proliferation of cells (from Explanatory Sentence 1)\\nC: \u03b2-catenin (from Explanatory Sentence 1)\\nD: inhibiting \u03b2-catenin (from Explanatory Sentence 2)\\nE: reduction or cessation of cell proliferation (from Explanatory Sentence 2)\\nF: treatment for activating CTNNB1 mutations (from Explanatory Sentence 2)\\nG: addressing the underlying cause of cell proliferation (from Explanatory Sentence 3)\\nH: effectiveness of treatment (from Explanatory Sentence 5)\\n\\nLogical Relations:\\nImplies(A, Implies(C, B))\\nImplies(activating mutations of CTNNB1, Implies(\u03b2-catenin, proliferation of cells))\\n--------\\nImplies(D, E)\\nImplies(inhibiting \u03b2-catenin, reduction or cessation of cell proliferation)\\n--------\\nImplies(E, F)\\nImplies(reduction or cessation of cell proliferation, treatment for activating CTNNB1 mutations)\\n--------\\nImplies(E, G)\\nImplies(reduction or cessation of cell proliferation, addressing the underlying cause of cell proliferation)\\n--------\\nImplies(D, H)\\nImplies(inhibiting \u03b2-catenin, effectiveness of treatment)\\n--------\\nImplies(D, F)\\nImplies(inhibiting \u03b2-catenin, treatment for activating CTNNB1 mutations)\\n--------\\n\\nDerived Implications:\\nImplies(D, G)\\nImplies(inhibiting \u03b2-catenin, addressing the underlying cause of cell proliferation)\\n--------\\nImplies(Not(G), Not(D))\\nImplies(Not(addressing the underlying cause of cell proliferation), Not(inhibiting \u03b2-catenin))\\n--------\\n'}",
            "8 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_30_8\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Mutations :: \"entity \u21d2 bool\"\\n  Activating :: \"entity \u21d2 bool\"\\n  CTNNB1 :: \"entity \u21d2 bool\"\\n  Proliferation :: \"entity \u21d2 bool\"\\n  Cells :: \"entity \u21d2 bool\"\\n  Promote :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Via :: \"entity \u21d2 entity \u21d2 bool\"\\n  \u03b2Catenin :: \"entity \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n  Reduce :: \"event \u21d2 bool\"\\n  Stop :: \"event \u21d2 bool\"\\n  Cause :: \"entity \u21d2 entity \u21d2 bool\"\\n  Reduction :: \"entity \u21d2 bool\"\\n  Cessation :: \"entity \u21d2 bool\"\\n  CrucialStep :: \"event \u21d2 bool\"\\n  Treat :: \"event \u21d2 bool\"\\n  Address :: \"event \u21d2 bool\"\\n  UnderlyingCause :: \"entity \u21d2 bool\"\\n  Directly :: \"event \u21d2 bool\"\\n  EffectiveTreatment :: \"event \u21d2 bool\"\\n  Effectiveness :: \"event \u21d2 bool\"\\n  Treatment :: \"event \u21d2 bool\"\\n  Ability :: \"event \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Pathway :: \"entity \u21d2 bool\"\\n  Lead :: \"entity \u21d2 entity \u21d2 bool\"\\n  Contribute :: \"event \u21d2 bool\"\\n  Success :: \"entity \u21d2 bool\"\\n  Thereby :: \"event \u21d2 bool\"\\n  Enhance :: \"event \u21d2 bool\"\\n  Responsible :: \"entity \u21d2 entity \u21d2 bool\"\\n  Ensure :: \"event \u21d2 bool\"\\n  Effective :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Activating mutations of CTNNB1 promote the proliferation of cells via \u03b2-catenin. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. Mutations x \u2227 Activating x \u2227 CTNNB1 x \u2227 Proliferation y \u2227 Cells z \u2227 Promote e \u2227 Agent e x \u2227 Patient e y \u2227 Via y z \u2227 \u03b2Catenin z\"\\n\\n(* Explanation 2: Inhibiting \u03b2-catenin can reduce or stop the proliferation of cells caused by activating mutations of CTNNB1, and this reduction or cessation is a crucial step in treating these mutations. *)\\naxiomatization where\\n  explanation_2_1: \"(\u2203x y z e1 e2. Inhibit e1 \u2227 \u03b2Catenin x \u2227 Agent e1 x \u2227 Proliferation y \u2227 Cells z \u2227 (Reduce e2 \u2228 Stop e2) \u2227 Agent e2 x \u2227 Patient e2 y \u2227 Cause y z \u2227 Mutations z \u2227 Activating z \u2227 CTNNB1 z)\"\\naxiomatization where\\n  explanation_2_2: \"(\u2203x y e. Reduction x \u2227 Cessation y \u2227 CrucialStep e \u2227 Treat e \u2227 Mutations x)\"\\n\\n(* Explanation 3: Reducing or stopping the proliferation of cells through inhibiting \u03b2-catenin directly addresses the underlying cause of cell proliferation, making it an effective treatment for patients with activating CTNNB1 mutations. *)\\naxiomatization where\\n  explanation_3_1: \"(\u2203x y z e1 e2. (Reduce e1 \u2228 Stop e1) \u2227 Proliferation x \u2227 Cells y \u2227 Inhibit e2 \u2227 \u03b2Catenin z \u2227 Agent e2 z \u2227 Address e1 \u2227 Cause x y \u2227 UnderlyingCause y \u2227 Directly e1)\"\\naxiomatization where\\n  explanation_3_2: \"(\u2203x y e. EffectiveTreatment e \u2227 Patient e x \u2227 Mutations x \u2227 Activating x \u2227 CTNNB1 x)\"\\n\\n(* Explanation 4: The effectiveness of inhibiting \u03b2-catenin as a treatment is due to its ability to target the specific pathway that leads to cell proliferation in patients with activating CTNNB1 mutations, thereby directly contributing to the treatment\\'s success. *)\\naxiomatization where\\n  explanation_4_1: \"(\u2203x y z e1 e2. Effectiveness e1 \u2227 Inhibit e2 \u2227 \u03b2Catenin x \u2227 Treatment e1 \u2227 Ability e2 \u2227 Target e2 \u2227 Pathway y \u2227 Lead y z \u2227 Proliferation z \u2227 Cells z \u2227 Patient e1 z \u2227 Mutations z \u2227 Activating z \u2227 CTNNB1 z)\"\\naxiomatization where\\n  explanation_4_2: \"(\u2203x e. Contribute e \u2227 Success x \u2227 Treatment x \u2227 Directly e \u2227 Thereby e)\"\\n\\n(* Explanation 5: Inhibiting \u03b2-catenin not only reduces cell proliferation but also enhances the effectiveness of treatment for patients with activating CTNNB1 mutations by directly targeting the pathway responsible for cell proliferation, ensuring the treatment is effective. *)\\naxiomatization where\\n  explanation_5_1: \"(\u2203x y z e1 e2 e3. Inhibit e1 \u2227 \u03b2Catenin x \u2227 Reduce e2 \u2227 Proliferation y \u2227 Cells y \u2227 Enhance e3 \u2227 Effectiveness z \u2227 Treatment z \u2227 Patient z y \u2227 Mutations y \u2227 Activating y \u2227 CTNNB1 y)\"\\naxiomatization where\\n  explanation_5_2: \"(\u2203x y e. Target e \u2227 Pathway x \u2227 Responsible x y \u2227 Proliferation y \u2227 Cells y \u2227 Directly e)\"\\naxiomatization where\\n  explanation_5_3: \"(\u2203x e. Ensure e \u2227 Treatment x \u2227 Effective x)\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"\u03b2Catenin x \u2227 Mutations y \u2227 Activating y \u2227 CTNNB1 y\"\\n  (* Hypothesis: Inhibiting \u03b2-catenin may be effective in treating patients with activating CTNNB1 mutations *)\\n  shows \"\u2203x y e1 e2. Inhibit e1 \u2227 \u03b2Catenin x \u2227 Agent e1 x \u2227 Effective e2 \u2227 Treat e2 \u2227 Patient e2 y \u2227 Mutations y \u2227 Activating y \u2227 CTNNB1 y\"\\nproof -\\n  (* From the known information, we have \u03b2Catenin x, Mutations y, Activating y, and CTNNB1 y. *)\\n  from asm have \"\u03b2Catenin x \u2227 Mutations y \u2227 Activating y \u2227 CTNNB1 y\" <ATP>\\n  \\n  (* Explanation 2 states that inhibiting \u03b2-catenin can reduce or stop the proliferation of cells caused by activating mutations of CTNNB1. *)\\n  (* This reduction or cessation is a crucial step in treating these mutations. *)\\n  (* We have the logical relation Implies(D, E) and Implies(E, F), which means inhibiting \u03b2-catenin leads to treatment for activating CTNNB1 mutations. *)\\n  then have \"\u2203e1. Inhibit e1 \u2227 \u03b2Catenin x \u2227 Agent e1 x \u2227 Mutations y \u2227 Activating y \u2227 CTNNB1 y\" <ATP>\\n  \\n  (* Explanation 4 and the logical relation Implies(D, G) indicate that inhibiting \u03b2-catenin leads to the effectiveness of treatment. *)\\n  (* Therefore, we can infer the effectiveness of the treatment. *)\\n  then have \"\u2203e2. Effective e2 \u2227 Treat e2 \u2227 Patient e2 y \u2227 Mutations y \u2227 Activating y \u2227 CTNNB1 y\" <ATP>\\n  \\n  (* Combining the above steps, we can conclude the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: activating mutations of CTNNB1 (from Explanatory Sentence 1)\\nB: proliferation of cells (from Explanatory Sentence 1)\\nC: \u03b2-catenin (from Explanatory Sentence 1)\\nD: inhibiting \u03b2-catenin (from Explanatory Sentence 2)\\nE: reduction or cessation of cell proliferation (from Explanatory Sentence 2)\\nF: treatment for activating CTNNB1 mutations (from Explanatory Sentence 2)\\nG: effectiveness of treatment (from Explanatory Sentence 4)\\nH: targeting the specific pathway (from Explanatory Sentence 4)\\n\\nLogical Relations:\\nImplies(A, Implies(C, B))\\nImplies(activating mutations of CTNNB1, Implies(\u03b2-catenin, proliferation of cells))\\n--------\\nImplies(D, E)\\nImplies(inhibiting \u03b2-catenin, reduction or cessation of cell proliferation)\\n--------\\nImplies(E, F)\\nImplies(reduction or cessation of cell proliferation, treatment for activating CTNNB1 mutations)\\n--------\\nImplies(D, H)\\nImplies(inhibiting \u03b2-catenin, targeting the specific pathway)\\n--------\\nImplies(H, G)\\nImplies(targeting the specific pathway, effectiveness of treatment)\\n--------\\nImplies(D, G)\\nImplies(inhibiting \u03b2-catenin, effectiveness of treatment)\\n--------\\n\\nDerived Implications:\\nImplies(D, F)\\nImplies(inhibiting \u03b2-catenin, treatment for activating CTNNB1 mutations)\\n--------\\nImplies(Not(F), Not(D))\\nImplies(Not(treatment for activating CTNNB1 mutations), Not(inhibiting \u03b2-catenin))\\n--------\\n'}",
            "9 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_30_9\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Mutation :: \"entity \u21d2 bool\"\\n  Activating :: \"entity \u21d2 bool\"\\n  CTNNB1 :: \"entity \u21d2 bool\"\\n  Cell :: \"entity \u21d2 bool\"\\n  \u03b2Catenin :: \"entity \u21d2 bool\"\\n  Proliferation :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Via :: \"event \u21d2 entity \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n  Cause :: \"event \u21d2 entity \u21d2 bool\"\\n  Reduce :: \"event \u21d2 bool\"\\n  Stop :: \"event \u21d2 bool\"\\n  Reduction :: \"event \u21d2 bool\"\\n  Cessation :: \"event \u21d2 bool\"\\n  Treat :: \"event \u21d2 bool\"\\n  CrucialStep :: \"event \u21d2 event \u21d2 bool\"\\n  Address :: \"event \u21d2 entity \u21d2 bool\"\\n  Directly :: \"event \u21d2 bool\"\\n  Make :: \"event \u21d2 bool\"\\n  Effective :: \"event \u21d2 bool\"\\n  Treatment :: \"event \u21d2 bool\"\\n  Purpose :: \"event \u21d2 entity \u21d2 bool\"\\n  Pathway :: \"entity \u21d2 bool\"\\n  Lead :: \"event \u21d2 entity \u21d2 bool\"\\n  Contribute :: \"event \u21d2 bool\"\\n  Success :: \"event \u21d2 bool\"\\n  Thereby :: \"event \u21d2 bool\"\\n  Enhance :: \"event \u21d2 event \u21d2 bool\"\\n  Target :: \"event \u21d2 entity \u21d2 bool\"\\n  Responsible :: \"event \u21d2 entity \u21d2 bool\"\\n  By :: \"event \u21d2 bool\"\\n  Ensure :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Activating mutations of CTNNB1 promote the proliferation of cells via \u03b2-catenin. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. Mutation x \u2227 Activating x \u2227 CTNNB1 y \u2227 Cell z \u2227 \u03b2Catenin y \u2227 Proliferation e \u2227 Agent e x \u2227 Patient e z \u2227 Via e y\"\\n\\n(* Explanation 2: Inhibiting \u03b2-catenin can reduce or stop the proliferation of cells caused by activating mutations of CTNNB1, and this reduction or cessation is a crucial step in treating these mutations. *)\\naxiomatization where\\n  explanation_2_1: \"\u2203x y z e1 e2. Inhibit e1 \u2227 \u03b2Catenin x \u2227 Cell y \u2227 Mutation z \u2227 Activating z \u2227 CTNNB1 z \u2227 Proliferation e2 \u2227 Agent e1 x \u2227 Patient e2 y \u2227 Cause e2 z \u27f6 (Reduce e1 \u2228 Stop e1)\"\\naxiomatization where\\n  explanation_2_2: \"\u2203x y e1 e2. Reduction e1 \u2227 Cessation e1 \u2227 Mutation x \u2227 Treat e2 \u2227 Agent e2 y \u2227 Patient e2 x \u27f6 CrucialStep e1 e2\"\\n\\n(* Explanation 3: Reducing or stopping the proliferation of cells through inhibiting \u03b2-catenin directly addresses the underlying cause of cell proliferation, making it an effective treatment for patients with activating CTNNB1 mutations. *)\\naxiomatization where\\n  explanation_3_1: \"\u2203x y z e1 e2. (Reduce e1 \u2228 Stop e1) \u2227 Proliferation e2 \u2227 Cell x \u2227 Cause e2 y \u2227 Inhibit e1 \u2227 \u03b2Catenin z \u2227 Agent e1 z \u2227 Patient e2 x \u2227 Address e1 y \u2227 Directly e1\"\\naxiomatization where\\n  explanation_3_2: \"\u2203x y z e1 e2. Make e1 \u2227 Effective e2 \u2227 Treatment e2 \u2227 Patient e2 x \u2227 Mutation y \u2227 Activating y \u2227 CTNNB1 z \u2227 Agent e1 x \u2227 Patient e1 x \u2227 Purpose e1 y\"\\n\\n(* Explanation 4: The effectiveness of inhibiting \u03b2-catenin as a treatment is due to its ability to target the specific pathway that leads to cell proliferation in patients with activating CTNNB1 mutations, thereby directly contributing to the treatment\\'s success. *)\\naxiomatization where\\n  explanation_4_1: \"\u2203x y z w e1 e2 e3. Effective e1 \u2227 Inhibit e2 \u2227 \u03b2Catenin x \u2227 Treatment e1 \u2227 Pathway y \u2227 Cell z \u2227 Proliferation e3 \u2227 Patient e3 w \u2227 Mutation w \u2227 Activating w \u2227 CTNNB1 w \u2227 Target e2 y \u2227 Lead e3 z \u2227 Agent e2 x \u2227 Patient e3 z \u2227 Cause e1 w\"\\naxiomatization where\\n  explanation_4_2: \"\u2203x y e1 e2. Contribute e1 \u2227 Success e2 \u2227 Treatment e2 \u2227 Directly e1 \u2227 Thereby e1 \u2227 Agent e1 x \u2227 Patient e1 y\"\\n\\n(* Explanation 5: Inhibiting \u03b2-catenin not only reduces cell proliferation but also enhances the effectiveness of treatment for patients with activating CTNNB1 mutations by directly targeting the pathway responsible for cell proliferation, ensuring the treatment is effective. *)\\naxiomatization where\\n  explanation_5_1: \"\u2203x y z e1 e2 e3. Inhibit e1 \u2227 \u03b2Catenin x \u2227 Proliferation e2 \u2227 Cell y \u2227 Effective e3 \u2227 Treatment e3 \u2227 Patient e2 z \u2227 Mutation z \u2227 Activating z \u2227 CTNNB1 z \u2227 Reduce e1 \u2227 Enhance e1 e3 \u2227 Purpose e1 z\"\\naxiomatization where\\n  explanation_5_2: \"\u2203x y e1 e2. Target e1 x \u2227 Pathway x \u2227 Proliferation e2 \u2227 Cell y \u2227 Responsible e2 x \u2227 Directly e1 \u2227 By e1 \u2227 Agent e1 x \u2227 Patient e1 y\"\\naxiomatization where\\n  explanation_5_3: \"\u2203x e. Ensure e \u2227 Treatment x \u2227 Effective x \u2227 Agent e x\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"\u03b2Catenin x \u2227 Patient e1 y \u2227 Mutation y \u2227 Activating y\"\\n  (* Hypothesis: Inhibiting \u03b2-catenin may be effective in treating patients with activating CTTNB1 mutations *)\\n  shows \"\u2203x y e1 e2. Inhibit e1 \u2227 \u03b2Catenin x \u2227 Patient e1 y \u2227 Mutation y \u2227 Activating y \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Treat e2 \u2227 Agent e2 x \u2227 Patient e2 y \u27f6 Effective e2\"\\nproof -\\n  (* From the known information, we have \u03b2Catenin x, Patient e1 y, Mutation y, and Activating y. *)\\n  from asm have \"\u03b2Catenin x \u2227 Patient e1 y \u2227 Mutation y \u2227 Activating y\" <ATP>\\n  (* We need to show that inhibiting \u03b2-catenin may be effective in treating patients with activating CTNNB1 mutations. *)\\n  (* From the logical relation Implies(D, H), we know that inhibiting \u03b2-catenin implies the effectiveness of treatment. *)\\n  (* We also have Implies(D, F), which means inhibiting \u03b2-catenin implies treatment for activating CTNNB1 mutations. *)\\n  (* Therefore, if we can show that inhibiting \u03b2-catenin occurs, we can conclude the effectiveness of treatment. *)\\n  (* From the derived implication Implies(D, H), we can directly infer the effectiveness of treatment. *)\\n  have \"Inhibit e1 \u2227 \u03b2Catenin x \u2227 Patient e1 y \u2227 Mutation y \u2227 Activating y \u27f6 Effective e2\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: activating mutations of CTNNB1 (from Explanatory Sentence 1)\\nB: proliferation of cells (from Explanatory Sentence 1)\\nC: \u03b2-catenin (from Explanatory Sentence 1)\\nD: inhibiting \u03b2-catenin (from Explanatory Sentence 2)\\nE: reduction or cessation of cell proliferation (from Explanatory Sentence 2)\\nF: treatment for activating CTNNB1 mutations (from Explanatory Sentence 2)\\nG: addressing the underlying cause of cell proliferation (from Explanatory Sentence 3)\\nH: effectiveness of treatment (from Explanatory Sentence 4)\\nI: targeting the specific pathway (from Explanatory Sentence 4)\\n\\nLogical Relations:\\nImplies(A, Implies(C, B))\\nImplies(activating mutations of CTNNB1, Implies(\u03b2-catenin, proliferation of cells))\\n--------\\nImplies(D, Or(E, Not(B)))\\nImplies(inhibiting \u03b2-catenin, E | ~B)\\n--------\\nImplies(E, F)\\nImplies(reduction or cessation of cell proliferation, treatment for activating CTNNB1 mutations)\\n--------\\nImplies(D, G)\\nImplies(inhibiting \u03b2-catenin, addressing the underlying cause of cell proliferation)\\n--------\\nImplies(I, H)\\nImplies(targeting the specific pathway, effectiveness of treatment)\\n--------\\nImplies(D, And(E, H))\\nImplies(inhibiting \u03b2-catenin, E & H)\\n--------\\n\\nDerived Implications:\\nImplies(Not(F), Not(D))\\nImplies(Not(treatment for activating CTNNB1 mutations), Not(inhibiting \u03b2-catenin))\\n--------\\nImplies(Not(H), Not(D))\\nImplies(Not(effectiveness of treatment), Not(inhibiting \u03b2-catenin))\\n--------\\nImplies(D, E)\\nImplies(inhibiting \u03b2-catenin, reduction or cessation of cell proliferation)\\n--------\\nImplies(D, F)\\nImplies(inhibiting \u03b2-catenin, treatment for activating CTNNB1 mutations)\\n--------\\nImplies(Not(E), Not(D))\\nImplies(Not(reduction or cessation of cell proliferation), Not(inhibiting \u03b2-catenin))\\n--------\\nImplies(D, H)\\nImplies(inhibiting \u03b2-catenin, effectiveness of treatment)\\n--------\\n'}",
            "10 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 4.0883893966674805, 'proof tactics': ['Type unification failed: Clash of types \"entity\" and \"event\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  Treat :: event \\\\<Rightarrow> bool\\nOperand:   e2 :: entity\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_30_10\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Mutations :: \"entity \u21d2 bool\"\\n  Activating :: \"entity \u21d2 bool\"\\n  CTNNB1 :: \"entity \u21d2 bool\"\\n  Proliferation :: \"entity \u21d2 bool\"\\n  Cells :: \"entity \u21d2 bool\"\\n  Promote :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  \u03b2Catenin :: \"entity \u21d2 bool\"\\n  Via :: \"event \u21d2 entity \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n  Reduce :: \"event \u21d2 bool\"\\n  Stop :: \"event \u21d2 bool\"\\n  Cause :: \"entity \u21d2 entity \u21d2 bool\"\\n  Reduction :: \"entity \u21d2 bool\"\\n  Cessation :: \"entity \u21d2 bool\"\\n  CrucialStep :: \"event \u21d2 bool\"\\n  Treat :: \"event \u21d2 bool\"\\n  Address :: \"event \u21d2 bool\"\\n  Directly :: \"event \u21d2 bool\"\\n  EffectiveTreatment :: \"event \u21d2 bool\"\\n  Effectiveness :: \"event \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Ability :: \"event \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Pathway :: \"entity \u21d2 bool\"\\n  Lead :: \"entity \u21d2 entity \u21d2 bool\"\\n  Contribute :: \"event \u21d2 bool\"\\n  Success :: \"entity \u21d2 bool\"\\n  Enhance :: \"event \u21d2 bool\"\\n  Responsible :: \"entity \u21d2 entity \u21d2 bool\"\\n  Ensure :: \"event \u21d2 bool\"\\n  Effective :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Activating mutations of CTNNB1 promote the proliferation of cells via \u03b2-catenin. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. Mutations x \u2227 Activating x \u2227 CTNNB1 x \u2227 Proliferation y \u2227 Cells y \u2227 Promote e \u2227 Agent e x \u2227 Patient e y \u2227 \u03b2Catenin z \u2227 Via e z\"\\n\\n(* Explanation 2: Inhibiting \u03b2-catenin can reduce or stop the proliferation of cells caused by activating mutations of CTNNB1, and this reduction or cessation is a crucial step in treating these mutations. *)\\naxiomatization where\\n  explanation_2_1: \"\u2203x y z e1 e2. Inhibit e1 \u2227 \u03b2Catenin x \u2227 Agent e1 x \u2227 Proliferation y \u2227 Cells y \u2227 (Reduce e2 \u2228 Stop e2) \u2227 Agent e2 x \u2227 Patient e2 y \u2227 Mutations z \u2227 Activating z \u2227 CTNNB1 z \u2227 Cause z y\"\\naxiomatization where\\n  explanation_2_2: \"\u2203x y e. Reduction x \u2227 Cessation y \u2227 CrucialStep e \u2227 Treat e \u2227 Mutations y\"\\n\\n(* Explanation 3: Reducing or stopping the proliferation of cells through inhibiting \u03b2-catenin directly addresses the underlying cause of cell proliferation, making it an effective treatment for patients with activating CTNNB1 mutations. *)\\naxiomatization where\\n  explanation_3_1: \"\u2203x y z e1 e2. (Reduce e1 \u2228 Stop e1) \u2227 Proliferation x \u2227 Cells x \u2227 Inhibit e2 \u2227 \u03b2Catenin y \u2227 Agent e2 y \u2227 Cause z y \u2227 Address e1 \u2227 Patient e1 z \u2227 Directly e1\"\\naxiomatization where\\n  explanation_3_2: \"\u2203x y e. EffectiveTreatment e \u2227 Patient e x \u2227 Mutations y \u2227 Activating y \u2227 CTNNB1 y\"\\n\\n(* Explanation 4: The effectiveness of inhibiting \u03b2-catenin as a treatment is due to its ability to target the specific pathway that leads to cell proliferation in patients with activating CTNNB1 mutations, thereby directly contributing to the treatment\\'s success. *)\\naxiomatization where\\n  explanation_4_1: \"\u2203x y z e1 e2 e3. Effectiveness e1 \u2227 Inhibit e2 \u2227 \u03b2Catenin x \u2227 Agent e2 x \u2227 Treatment z \u2227 Ability e3 \u2227 Target e3 \u2227 Pathway y \u2227 Lead y z \u2227 Proliferation z \u2227 Cells z \u2227 Patient e3 y \u2227 Mutations y \u2227 Activating y \u2227 CTNNB1 y\"\\naxiomatization where\\n  explanation_4_2: \"\u2203x e. Contribute e \u2227 Success x \u2227 Treatment x \u2227 Directly e\"\\n\\n(* Explanation 5: Inhibiting \u03b2-catenin not only reduces cell proliferation but also enhances the effectiveness of treatment for patients with activating CTNNB1 mutations by directly targeting the pathway responsible for cell proliferation, ensuring the treatment is effective. *)\\naxiomatization where\\n  explanation_5_1: \"\u2203x y z e1 e2 e3. Inhibit e1 \u2227 \u03b2Catenin x \u2227 Agent e1 x \u2227 Proliferation y \u2227 Cells y \u2227 Reduce e2 \u2227 Agent e2 x \u2227 Patient e2 y \u2227 Effectiveness z \u2227 Treatment y \u2227 Enhance e3 \u2227 Agent e3 x \u2227 Patient e3 y \u2227 Mutations y \u2227 Activating y \u2227 CTNNB1 y\"\\naxiomatization where\\n  explanation_5_2: \"\u2203x y e. Target e \u2227 Pathway x \u2227 Responsible x y \u2227 Proliferation y \u2227 Cells y \u2227 Directly e\"\\naxiomatization where\\n  explanation_5_3: \"\u2203x e. Ensure e \u2227 Treatment x \u2227 Effective x\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"\u03b2Catenin x \u2227 Mutations y \u2227 Activating y \u2227 CTNNB1 y\"\\n  (* Hypothesis: Inhibiting \u03b2-catenin may be effective in treating patients with activating CTNNB1 mutations *)\\n  shows \"\u2203x y e1 e2. Inhibit e1 \u2227 \u03b2Catenin x \u2227 Agent e1 x \u2227 Effective e2 \u2227 Treat e2 \u2227 Patient e2 y \u2227 Mutations y \u2227 Activating y \u2227 CTNNB1 y\"\\nproof -\\n  (* From the premise, we have known information about \u03b2-catenin and activating mutations of CTNNB1. *)\\n  from asm have \"\u03b2Catenin x \u2227 Mutations y \u2227 Activating y \u2227 CTNNB1 y\" <ATP>\\n  (* There is a logical relation Implies(D, F), Implies(inhibiting \u03b2-catenin, treatment for activating CTNNB1 mutations) *)\\n  (* Explanation 2 supports that inhibiting \u03b2-catenin can lead to treatment for activating CTNNB1 mutations. *)\\n  have \"\u2203e1. Inhibit e1 \u2227 \u03b2Catenin x \u2227 Agent e1 x \u2227 Treat e1 \u2227 Patient e1 y \u2227 Mutations y \u2227 Activating y \u2227 CTNNB1 y\" <ATP>\\n  (* There is a logical relation Implies(D, G), Implies(inhibiting \u03b2-catenin, effectiveness of treatment) *)\\n  (* Explanation 4 supports that inhibiting \u03b2-catenin contributes to the effectiveness of treatment. *)\\n  then have \"\u2203e2. Effective e2 \u2227 Treat e2 \u2227 Patient e2 y \u2227 Mutations y \u2227 Activating y \u2227 CTNNB1 y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: activating mutations of CTNNB1 (from Explanatory Sentence 1)\\nB: proliferation of cells (from Explanatory Sentence 1)\\nC: \u03b2-catenin (from Explanatory Sentence 1)\\nD: inhibiting \u03b2-catenin (from Explanatory Sentence 2)\\nE: reduction or cessation of cell proliferation (from Explanatory Sentence 2)\\nF: treatment for activating CTNNB1 mutations (from Explanatory Sentence 2)\\nG: effectiveness of treatment (from Explanatory Sentence 4)\\nH: targeting the specific pathway (from Explanatory Sentence 4)\\n\\nLogical Relations:\\nImplies(A, Implies(C, B))\\nImplies(activating mutations of CTNNB1, Implies(\u03b2-catenin, proliferation of cells))\\n--------\\nImplies(D, E)\\nImplies(inhibiting \u03b2-catenin, reduction or cessation of cell proliferation)\\n--------\\nImplies(E, F)\\nImplies(reduction or cessation of cell proliferation, treatment for activating CTNNB1 mutations)\\n--------\\nImplies(D, F)\\nImplies(inhibiting \u03b2-catenin, treatment for activating CTNNB1 mutations)\\n--------\\nImplies(H, G)\\nImplies(targeting the specific pathway, effectiveness of treatment)\\n--------\\nImplies(D, G)\\nImplies(inhibiting \u03b2-catenin, effectiveness of treatment)\\n--------\\n\\nDerived Implications:\\n'}"
        ]
    }
}